Malin Jonsson Fagerlund

Dr. Malin Jonsson Fagerlund

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2011 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NTNiccolò Terrando
Niccolò Terrando
LELars I. Eriksson
Lars I. Eriksson
JRJae Kyu Ryu
Jae Kyu Ryu
TYTing Yang
Ting Yang
CMClaudia Monaco
Claudia Monaco
MMMervyn Maze
Mervyn Maze

8 April 2017 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
IGI.-M. Gustafsson
I.-M. Gustafsson
ÅLÅ. Lodenius
Å. Lodenius
JTJ. Tunelli
J. Tunelli
JUJ. Ullman
J. Ullman
MFMalin Jonsson Fagerlund
Malin Jonsson Fagerlund
Background. Apnoeic oxygenation during anaesthesia has traditionally been limited by the rapid increase in carbon dioxide and subsequent decrease in pH. Using a Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) technique a slower increase in carbon dioxide than earlier studies was seen. Notably, apnoeic oxygenation using THRIVE has not been systematically evaluated with arterial blood gases or in patients undergoing laryngeal surgery. The primary aim of this study was to characterize changes in arterial PO2, PCO2 and pH during apnoeic oxygenation using THRIVE under general anaesthesia. Methods. Adult patients, (ASA I-II), undergoing shorter laryngeal surgery under general anaesthesia, were oxygenated during apnoea using THRIVE, 100% oxygen, 40–70 litres min−1. A cohort was randomized to hyperventilate during pre-oxygenation. Vital parameters and blood gases were monitored. Results. Thirty-one patients, age 51 (34–76) yr, BMI 25 (4) were included. Mean apnoea time was 22.5 (4.5) min. Patients were well oxygenated, SpO2 was never below 91%. The increase in PaCO2 and end-tidal CO2 during apnoea was 0.24 (0.05) and 0.12 (0.04) kPa min−1, respectively. Hyperventilation during pre-oxygenation generated no difference in PaCO2 at the end of apnoea compared with normoventilation. Conclusions. This physiological study of apnoeic oxygenation using THRIVE during laryngeal surgery shows that this technique is able to keep patients with mild systemic disease and a BMI <30 well oxygenated for a period of up to 30 min. The THRIVE concept makes it possible to extend the apnoeic window but monitoring of CO2 and/or pH is recommended. Clinical trial registration. NCT02706431.

23 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SRSusanne Rysz
Susanne Rysz
JAJonathan Al-Saadi
Jonathan Al-Saadi
ASAnna Sjöström
Anna Sjöström
MFMaria Farm
Maria Farm
FJFrancesca Campoccia Jalde
Francesca Campoccia Jalde
JLJohan Lundberg
Johan Lundberg
SARS-CoV-2 uses ACE2, an inhibitor of the Renin-Angiotensin-Aldosterone System (RAAS), for cellular entry. Studies indicate that RAAS imbalance worsens the prognosis in COVID-19. We present a consecutive retrospective COVID-19 cohort with findings of frequent pulmonary thromboembolism (17%), high pulmonary artery pressure (60%) and lung MRI perfusion disturbances. We demonstrate, in swine, that infusing angiotensin II or blocking ACE2 induces increased pulmonary artery pressure, reduces blood oxygenation, increases coagulation, disturbs lung perfusion, induces diffuse alveolar damage, and acute tubular necrosis compared to control animals. We further demonstrate that this imbalanced state can be ameliorated by infusion of an angiotensin receptor blocker and low-molecular-weight heparin. In this work, we show that a pathophysiological state in swine induced by RAAS imbalance shares several features with the clinical COVID-19 presentation. Therefore, we propose that severe COVID-19 could partially be driven by a RAAS imbalance.

13 February 2009 in Anaesthesia
Verified
Journal Article
Closed access
PDF file
JMJ. A. J. Martyn
J. A. J. Martyn
MFMalin Jonsson Fagerlund
Malin Jonsson Fagerlund
LEL. I. Eriksson
L. I. Eriksson

1 July 2009 in British Journal of Anaesthesia
Verified
Journal Article
Open access
PDF file
MFMalin Jonsson Fagerlund
Malin Jonsson Fagerlund
LEL. I. Eriksson
L. I. Eriksson
The neuromuscular junction (NMJ) is structured and powered to transduce electrical activity from the distal nerve terminal of a motor neurone via the neuromuscular cleft to the post-junctional muscle membrane to ultimately generate muscle contraction. Our understanding of this complex function has expanded over many years, and the NMJ has served as a prototype for how different synapses operate in the peripheral and central nervous systems. The NMJ has a presynaptic part which is synonymous with the distal nerve ending, being responsible for neurotransmitter synthesis, packaging into vesicles, and subsequent vesicle transportation to active release sites where vesicle docking, fusion, and release of acetylcholine and other co-released transmitters finally take place. The synaptic cleft, filled with large molecular complexes that guarantee ultrastructural NMJ arrangement and signal transduction, allows for rapid diffusion and degradation of the neurotransmitter. The postsynaptic part consists of a folded muscle membrane into which nicotinic acetylcholine receptors (nAChRs) directly opposite the presynaptic active release sites are mounted and fixed by a cytoskeleton. This specialized postsynaptic region is closely associated with the perijunctional zone where a high density of sodium channels promote and amplify the signal in order to guarantee the propagation of the electrical activity to generate muscle contraction. The transduction process is maintained at load (i.e. high stimulus frequency) by a presynaptic mechanism allowing for sustained transmitter release over time at high demand. This positive feedback mechanism relies on neuronal nAChRs present on the distal nerve terminal, whereas the continuation of the transduction process at the postsynaptic part relies on the classical muscle type nAChR. In this review, we will focus on recent findings of potential clinical importance that will advance our understanding of the effects of neuromuscular blocking agents and neuromuscular monitoring and also our management of disorders of the neuromuscular system within anaesthesia and intensive care.

20 August 2024 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
KKKunal Karamchandani
Kunal Karamchandani
Prashant NasaPrashant Nasa
Prashant Nasa
MJMary Jarzebowski
Mary Jarzebowski
DBDavid J. Brewster
David J. Brewster
AJAudrey De Jong
Audrey De Jong
HSHabib Srour
Habib Srour